"Latvia Pharmaceuticals & Healthcare Report Q4 2012" Now Available at Fast Market Research
BMI View: Despite a downward revision to our overall assessment of the size of Latvia's pharmaceutical market, we remain cautiously optimistic about the development of the market and our historic revisions have not had an overly significant impact on our growth projections over our five- and 10-year forecast periods. We have maintained our growth rate for 2012 of 4.0% in local currency terms, but we warn this is equivalent to a 5.2% contraction in US dollar terms. High out-of-pocket contributions...
View full press release